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ABSTRACT
Orphan nuclear receptor TR2 is a preadipocyte
proliferator. Knockdown of TR2 in 3T3-L1 preadipo-
cytes reduced their proliferation efficiency, whereas
specific elevation of TR2 in these cells facilitated
their proliferation. All-trans retinoic acid (RA)
stimulates cellular proliferation in 3T3-L1 preadipo-
cytes by activating TR2 through an IR0-type RA
response element, which further activates c-Myc
expression. In post-differentiated adipocytes, RA
becomes a repressive signal for TR2 and rapidly
down-regulates its expression. The biphasic effect
of RA on TR2 expression in 3T3-L1 is mediated by
differential RA-dependent coregulator recruitment
to the receptor/Glucocorticoid Receptor-Interacting
Protein 1 (GRIP1) complex that binds IR0 on the
TR2 promoter. RA induces the recruitment of
histone acetyl transferase-containing/GRIP1/p300/
CBP-associated factor (PCAF) complex to the
TR2 promoter in undifferentiated cells, whereas
it triggers recruitment of histone deacetylase-
containing/GRIP1/receptor-interacting protein 140
(RIP140) complex in differentiated cells. GRIP1
directly interacts with RIP140 through its carboxyl
terminal AD2 domain. GRIP1 interacts with PCAF
and RIP140 directly and differentially, functioning
as a platform molecule to mediate differential
RA-induced coregulator recruitment to TR2 promo-
ter target. This results in a biphasic effect of RA
on the expression of TR2 in undifferentiated
and differentiated cells, which is required for
RA-stimulated preadipocyte proliferation.
INTRODUCTION
The orphan nuclear receptor TR2 is a highly conserved
orphan member among the nuclear receptor superfamily.
Recent study of TR2-knockout animals revealed no
apparent developmental or pathological abnormalities in
animals housed in laboratory conditions (1). However,
results of in vitro studies of cultured cells ectopically
expressing TR2 suggested potential roles for TR2 in
a variety of cellular processes such as cell cycle (2,3),
apoptosis (4) and proliferation (5). In terms of gene
expression, mouse TR2 was found to be signiﬁcantly
elevated in early embryos (6), proliferating germ cells (7)
and P19 embryonal carcinoma stem cells (4,8,9).
Interestingly, its expression appeared to be regulated
primarily by an alteration in the vitamin A status in
animals, as well as by retinoic acid (RA), the principal
active ingredient of vitamin A, in cultured cells
(4,8,10,11). Using reporters, it was found that the
biological activity of TR2 largely overlapped with that
of RA receptor (RAR)/retinoid X receptor (RXR) (10,12).
Preliminary studies of TR2 have been conducted mostly
in P19 embryonal carcinoma stem cells (4,5) and 3T3-L1
embryonic ﬁbroblasts because of its speciﬁcally regulated
expression in these systems. These studies revealed a
somewhat atypical biphasic pattern of regulation of TR2
expression/activity by RA. Using reporter, gel mobility
shift and chromatin immunoprecipitation assays, we
located the principal RA-responsive element (RARE) in
the TR2 gene promoter to a region that contained an
inverted repeat with no nucleotide in the spacer (IR0)
(9,13). Following the discovery of a hormone-dependent
corepressor receptor-interacting protein 140 (RIP140)
(14), the biphasic regulation of this gene by RA was
further validated in reporter assays where RA could either
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the coexpression of diﬀerent ligand-dependent coregula-
tors. In the normal COS1 cellular environment where
PCAF and other potential coregulators were present, this
reporter was activated by RA as predicted (15). However,
with the addition of RIP140 into the system, RA
activation of this reporter was completely eliminated and
even further reduced (13,16).
Using highly puriﬁed protein preparations in a surface
plasmon resonance-based detection system for protein
interactions (BIAcore), we further evaluated the kinetic
parameters contributing to the formation of holo-
RAR–RXR–PCAF and holo-RAR–RXR–RIP140
complexes (17), In this highly puriﬁed system,
holo-RAR–RXR appeared to preferentially interact with
corepressor RIP140, as compared to PCAF, in an RA-
dependent manner. This was primarily attributed to a
greater on-rate in the formation of the holo-RAR–RXR–
RIP140 complex than the holo-RAR–RXR–PCAF
complex (17,18). Based upon these results, a working
model was proposed, that the exchange of diﬀerent types
of hormone-dependent coregulators underlined the
biphasic regulation of TR2 by the same hormone, RA.
The ﬁrst goal of this study was to test this model by
examining the diﬀerential RA-dependent coregulator-
recruiting patterns on the endogenous TR2 gene under
physiologically relevant conditions.
3T3-L1 preadipocytes diﬀerentiate into adipocytes that
store energy in the form of triglycerides. RA was shown
to repress adipocyte diﬀerentiation and/or stimulate
proliferation in preadipocytes (19–22). Unlike other cell
diﬀerentiation models, 3T3-L1 was usually induced by
a diﬀerentiation cocktail that included insulin, triiodothyr-
onine, dexamethasone and isobutylmethylxanthine but
not RA. In fact, RA and bone morphogenetic protein-2
could cooperate to repress adipocyte diﬀerentiation,
stimulate proliferation and induce osteoblast diﬀerentia-
tion (21). Interestingly, TR2 was found to be regulated
by RA also in a biphasic pattern in this culture. Further,
RIP140 corepressor was not detected in the undiﬀeren-
tiated preadipocytes but was signiﬁcantly elevated during
adipogenesis (23). It was hypothesized that the elevation
of corepressor RIP140 in diﬀerentiated 3T3-L1 would
potentially create a repressive cellular environment for
RA-target genes such as TR2. Therefore, this culture
model provided an appropriate system to test our working
model of diﬀerential recruitment of various hormone-
dependent coregulators in a physiological context, as well
as the physiological function of TR2 in RA-signaling
pathway in terms of cell proliferation prior to adipocyte
diﬀerentiation.
Several categories of coregulatory proteins are known
for nuclear receptors and other transcription factors,
including members of the p160 family (steroid receptor
coactivator-1 [SRC-1], transcriptional intermediary
factor-2 [TIF2/Glucocorticoid Receptor-Interacting
Protein 1 (GRIP1), SRC-2] and SRC-3), coactivators
that encode or recruit histone acetyl transferases (HATs)
(e.g. p300/CBP, PCAF and GCN5) and histone methyl-
transferase (e.g. CARM1 and PRMT1) and corepressors,
some of which encode or recruit histone deacetylases
(HDACs). It is generally believed that the coregulatory
complexes are highly dynamic and the compositions
of coregulatory complexes change as genes are subjected
to diﬀerent regulatory events. The general principle of
complex formation describes the recruitment of corepres-
sors by aporeceptors and the recruitment of coactivators
by holoreceptors (24,25), which holds true for typical
hormone-activation of target genes. However, for the
increasingly known hormonal repression of certain direct
target genes, it remains unclear whether and how diﬀerent
hormone-dependent coregulators exchange on the target
genes in the continuous presence of the hormone. It is
crucial to elucidate the underlying molecular mechan-
isms of this phenomenon in a physiologically relevant
context.
In this study, we ﬁrst observed the functional role for
TR2 in mediating 3T3-L1 preadipocyte proliferation and
addressed the biphasic eﬀect of RA on TR2 expression
in the 3T3-L1 culture. This occurs because of the
RA-dependent replacement of coactivator PCAF with
corepressor RIP140 on a platform molecule GRIP1.
We then showed that GRIP1 itself provided no activating
or repressive activity; rather it served as a component
of a platform complex by directly and diﬀerentially
interacting with the diﬀerent RA-dependent coregulators.
The results of these studies consistently suggested
a potential role for TR2 in mediating the physiological
activity of vitamin A, or more speciﬁcally, RA. Previously,
this theory has been viewed as speculative, largely because
of the lack of studies to demonstrate its relationship
with RA signaling in a physiologically relevant system.
For this purpose, our results elucidated cell proliferation
as the most likely target of TR2 in the 3T3-L1 system,
which appeared to be closely modulated by the biphasic
regulation of TR2 by RA in this commonly used cell
culture model.
MATERIALS AND METHODS
Construction of expression vector and TR2-inducible
3T3-L1 clones
Mammalian expression vector of RAR, RXR, PCAF,
GRIP1, RIP140 and IR0-tk-luciferase reporter, and GST
constructs of RIP140 has been described earlier (13,16).
GRIP1 constructs in pSG5.HA expression vector were a
generous gift from Michael R. Stallcup (26). For isolation
of TR2-inducible clones, 3T3-L1 cells transfected with
pTet-On (Clontech) and pTRE-TR2 were selected by
treatment with 500mg/ml of G418 for 14 days. TR2 was
induced by adding tetracycline (1mg/ml). A 1mM
working concentration of all-trans RA was used in all
experiments (21) inasmuch as low concentrations (1pM
to 10nM) are known to have opposite eﬀects on
adipogenesis (27).
Cell cultureand cell proliferation assay
3T3-L1 cells were maintained and diﬀerentiated by
diﬀerentiation cocktail that included insulin, triiodothyr-
onine, dexamethasone and isobutylmethylxanthine as
described earlier (28). For cell proliferation, a thymidine
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after TR2 silencing or induction, cells were synchronized
in DMEM supplemented with 1% calf serum for 6h. Cells
were grown in regular growth media for an additional 2h
prior to addition of 1mCi
3H-thymidine for 6h. Cells were
washed twice with PBS, once with ice-cold 10% TCA and
two more times with PBS. Finally, cells were lysed in
500ml of 2N NaOH for over 6h and samples were
analyzed by a scintillation counter. Qualitative estimation
of triglycerides was performed by oil-red-O staining.
Quantitative determination of triglycerides was performed
by alkaline hydrolysis and measurement of glycerol
released by the Free Glycerol Determination Kit (Sigma).
RT-PCR and RNA interference
To monitor the expression of TR2–GRIP1–PCAF–
RIP140at the mRNA level, total RNA was isolated
from 3T3-L1 cells using a TRIzol kit (Invitrogen) and
RT-PCR was conducted as described earlier (16).
Primers speciﬁc to TR2 (14), GRIP1 (sense, 50-AACCA
ACACCTTCGGCAGAG-30 and antisense, 50-TTCATG
CTGCTCAAGCCAC-30), PCAF (sense, 50-CACTTGG
AGAATGTGTCAAGAG-30 and antisense, 50-GATGGT
GAAGACCGAGCGAA-30) and RIP140 (sense, 50-AAC
ACGAGCTATAAGAATCA-30 and antisense, 50-CAAC
TGAAGAAGAGTGAC-30) were used. Actin-speciﬁc
primers (29) were included as internal controls in each
RT-PCR. 3T3-L1 cells were transfected with scrambled
RNA (Dharmacon) or TR2-speciﬁc siRNA (50-GCACCA
GAUAAGGCUGAAUTT-30/50-TTCGUGGUCCUAU
UCGACUUA-30) using DharmaFECT 3 (Dharmacon)
for 72h. Total RNA or proteins were analyzed by
RT-PCR or western blot.
Immunoprecipitation and western blot analyses
Immunoprecipitation and western blot assays were
performed as described earlier (15).  RA-induced endo-
genous complexes on RAR–RXR in preadipocytes/
diﬀerentiated 3T3-L1 were precipitated with anti-RAR
(Santa Cruz Biotechnology). For experiments requiring
double immunoprecipitation, RAR immunoprecipitates
on protein G beads were washed two times with pre-
elution buﬀer, followed by elution/solubilization in 100ml
of low pH buﬀer (100mM glycine, pH 2.5) with immediate
neutralization in collection buﬀer (1/20 volume phos-
phate, pH 8.0). The supernatant was diluted with
4 volumes of 10mM phosphate, pH 6.8 and subjected to
a second round of immunoprecipitation using anti-GRIP1
(Upstate Biotechnology). Beads were washed and resus-
pended in SDS loading buﬀer followed by western blot
analyses probed with anti-GRIP1, anti-PCAF (Santa Cruz
Biotechnology) and anti-RIP140 (30). Endogenous
expression of RAR, GRIP1, PCAF and RIP140 was
monitored by western blot analysis of cell lysates
and constituted the input. TR2 expression was probed
with anti-TR2 (Santa Cruz Biotechnology).
GST pull-down assays
Various GST–RIP140 constructs [full-length (amino
acids 1–1161), N-terminal (amino acids 1–496), central
(amino acids 333–1006), C-terminal (amino acids
977–1161)] were expressed and puriﬁed in E. coli and
bound to GST beads as described earlier (16). Washed
beads were incubated with in vitro-transcribed and
translated (Promega) [
35S] Met-labeled GRIP1 constructs
[full-length (amino acids 1–1462), N-terminal (amino acids
5–479), extended N-terminal (amino acids 5–765), central
(amino acids 563–1121), C-terminal (amino acids
1122–1462)]. After extensively washing with the binding
buﬀer, speciﬁcally bound proteins were resolved by
SDS-PAGE and detected with a Phosphorimager. Equal
volumes subjected to SDS-PAGE and stained with
Coomassie blue constituted the GST input. Also, each
sample of in vitro transcription-coupled translation
was subjected to SDS-PAGE and detected with a
Phosphorimager and constituted TNT input (30%).
HAT and HDACenzymatic assays
Deacetylase and acetylase activity was measured in
the samples using a kit (Upstate Biotechnology) according
to the manufacturer’s instructions with some adaptations.
For HAT assays, RA-induced RAR-associated complexes
were precipitated with RAR antibody and incubated with
HAT assay buﬀer 5 ,1 0mg of histone (Sigma), 3.2mCi of
[
3H]-acetyl CoA and an appropriate volume of deionized
water. After mixing the contents, the tubes were incubated
at 308C for 3–4h on a rotating platform. The reaction
mixture was centrifuged and the supernatant was resolved
on a 20% SDS-polyacrylamide gel by electrophoresis.
Gels were soaked in 1M sodium salicylate (enhancer),
dried and exposed to ﬁlms. The dried gels were
resuspended in water and stained with Coomassie blue
to determine histone (substrate) input. The pellets were
probed for RAR and constituted the RAR-complex
(enzyme) input. For the HDAC activity, precipitated
RAR complexes were incubated with 50000 C.P.M
(counts per minute) of a biotin-conjugated [
3H]-acetyl
histone-H4 peptide bound to a streptavidin-agarose
slurry. The mix was incubated at 378C on a rotating
platform for 6h. The reaction was stopped by addition of
a quenching solution and the beads were collected by
centrifugation. The released [
3H]-acetate in the super-
natant was monitored by scintillation counter.
Transfectionand reporter assays
Transfection and speciﬁc reporter assays conducted in
COS1 cells were as described (13,31).
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were conducted as described (32) with slight
modiﬁcations to examine RA-induced complexes on
endogenous TR2 promoter (IRO) in preadipocyte and
diﬀerentiated 3T3-L1. Antibodies against GRIP1,
HDAC3, acetylated histone H3, RNA-Pol II, PCAF
from Upstate Biotechnology and RIP140 (30) were used.
For repeated ChIP assays, chromatin DNA precipitated
with anti-GRIP1 was eluted, and subjected to repeated
immunoprecipitation with the second antibody followed
by classical ChIP protocol. Five percent of total DNA
was used in the input. Collected DNA was ampliﬁed with
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of the endogenous TR2 gene (sense, 50-CCGCCGCTGGA
CTCCGGGGCCCTC30 and antisense, 50-CGCTGGGCT
GGAGAGAGCAGAGGC30) (13).
RESULTS
TR2function in 3T3-L1 preadipocyteproliferation
To determine the functional role for TR2 in proliferating
3T3-L1 preadipocytes, we ﬁrst employed gain- and
loss-of-function strategies using tetracycline-inducible
expression and RNA interference (RNAi)-mediated silen-
cing in undiﬀerentiated 3T3-L1 preadipocytes. The results
of loss-of-function studies are shown in Figure 1A.
Approximately 80% knockdown of TR2 mRNA
expression and 60% knockdown of TR2 protein levels
(left panel) reduced the rate of thymidine incorporation
in these cultures by approximately 50% (right panel).
For gain-of-function experiments, several stable
tetracycline-inducible TR2-expressing clones were exam-
ined (Figure 1B). The rate of thymidine incorporation into
these cultures was increased on average by approximately
3-fold after 24h of TR2 induction. These results showed
a causal eﬀect of TR2 on the increased preadipocyte
proliferation in the 3T3-L1 model.
Biphasic regulation ofTR2 inthe 3T3-L1differentiation
model and differential expression ofcoregulators
To decipher events upstream of TR2 gene expression
in preadipocytes, we found that RA increased its
transcriptional eﬃciency and, as expected, increased cell
proliferation (Figure 2A). Very interestingly, RA exerted
a biphasic eﬀect on the expression of TR2 in 3T3-L1 in
relationship to its diﬀerentiation (Figure 2B). TR2 was
induced by RA in undiﬀerentiated cells but repressed
by RA in diﬀerentiated cells. This was probably due to
the diﬀerent types of coregulators expressed in 3T3-L1,
before and after diﬀerentiation, might be diﬀerent.
The expression patterns of several endogenous coregula-
tors for RAR–RXR and the eﬀects of RA on the
expression of these endogenous components in 3T3-L1
cells before and after diﬀerentiation were then examined
as shown in Figure 2B. Interestingly, the expression levels
of the endogenous coactivators PCAF and GRIP1 were
maintained at relatively constant levels during the course
of RA induction in cells before and after diﬀerentiation.
In contrast, RIP140 was not detectable during the entire
course of RA treatment in the undiﬀerentiated cells
and was signiﬁcantly elevated in diﬀerentiated cells.
RA seemed to have little eﬀect on the expression of endo-
genous RIP140 in these diﬀerentiated cells. According to
our working model, the signiﬁcantly elevated expression
of RIP140 in diﬀerentiated cells would switch the cellular
environment from a condition suitable for hormonal
activation to that for hormonal repression. This would
explain the biphasic eﬀects of RA on the expression
of TR2, i.e. a rapid induction of TR2 by RA in
undiﬀerentiated cells followed by the second phase of
RA action in diﬀerentiated cells—a rapid repression
of TR2 by RA.
Different RA-dependent receptor–coregulator complexes in
3T3-L1 before andafter differentiation
To determine if RA induced the formation of diﬀerent
types of RA-dependent receptor–coregulator complexes
in undiﬀerentiated versus diﬀerentiated cells, sequential
co-immunoprecipitation (IP) procedures were carried out
to examine several key coregulatory components that
could be recruited by holo-RAR–RXR. While a number
of coactivators have been reported for RAR–RXR,
we focused on three components that are most relevant
to this system: the coactivators GRIP1–PCAF and
corepressor RIP140. Anti-RAR was used for the ﬁrst IP,
which apparently co-precipitated GRIP1 in both undiﬀer-
entiated and diﬀerentiated cells as shown on the western
blot probed with anti-GRIP1 (Figure 2C). RA enhanced
the formation of receptor–GRIP1 complex equally well in
cells both before and after diﬀerentiation (Figure 2C).
Figure 1. TR2 and preadipocyte proliferation. (A) TR2 was silenced by
RNAi in preadipocytes (left panel) and cell proliferation was monitored
by thymidine incorporation (right panel). (B) Tet-inducible TR2
expressing (top panel) 3T3-L1 clones were monitored for thymidine
incorporation (bottom panel) as cells were induced.
2272 Nucleic Acids Research, 2007, Vol. 35, No. 7Figure 2. Biphasic regulation of TR2 by RA and the formation of diﬀerent endogenous coregulator complexes in 3T3-L1. (A) At various time points
of RA treatment, TR2 protein levels were monitored by western blot (top panel) and preadipocyte proliferation conﬁrmed by thymidine
incorporation (bottom panel). (B) RT-PCR analyses of RA-induced TR2, but not coregulators, in preadipocytes and diﬀerentiated cells.
(C) Formation of diﬀerent coregulatory complexes in preadipocytes/diﬀerentiated 3T3L1. The ﬁrst immunoprecipitation was conducted using
anti-RAR and receptor-associated GRIP1 was monitored by western blot analysis. The RAR-associated complexes were subjected to a second round
of immunoprecipitation using anti-GRIP1, followed by western blot analysis of PCAF and RIP140.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2273The anti-RAR immunoprecipitated complex was subse-
quently precipitated with anti-GRIP1, followed by
western blot analyses using either anti-PCAF or anti-
RIP140. In undiﬀerentiated cells, PCAF formed
complexes with RAR–RXR–GRIP1 even without addi-
tional RA, contributing to the constitutive, basal level of
expression of TR2 in undiﬀerentiated cells. As predicted,
RA enhanced the level of PCAF recruitment to the
RAR–RXR–GRIP1 complex. Interestingly, while the
level of PCAF expression remained constant in both
undiﬀerentiated and diﬀerentiated cells as shown in
Figure 2B and C, PCAF apparently was dissociated
from the RAR–RXR–GRIP1 complex upon treatment
with RA in the diﬀerentiated cells. More importantly, in
the diﬀerentiated cells RIP140 was signiﬁcantly recruited
to the RAR–RXR–GRIP1 complex. The formation
of RAR–RXR–GRIP1–RIP140 complex was further
enhanced by RA treatment of diﬀerentiated cells despite
the constant expression of PCAF. As predicted, RIP140
was not detected on the RAR–RXR–GRIP1 complex in
undiﬀerentiated cells because RIP140 was not expressed
in these cells (Figure 2B and C). These results demon-
strated that RA induced the formation of diﬀerent
receptor–coregulator complexes in undiﬀerentiated
versus diﬀerentiated cells.
It was interesting to note that while both PCAF and
RIP140 were present in diﬀerentiated cells, the formation
of RIP140-containing complex was signiﬁcantly favored
over the formation of PCAF-containing complex by the
receptors, which was in agreement with our previous
kinetic studies that detected a higher binding aﬃnity
of holo-receptors toward RIP140 than PCAF (17).
This result suggested that the cellular environment could
be altered from a condition for hormone activation to that
for hormone repression by simply altering the expression
of a potent hormone-dependent corepressor RIP140.
To test this hypothesis, RIP140 was ectopically expressed
in the undiﬀerentiated cells. In these engineered
RIP140-expressing undiﬀerentiated cells, TR2 gene could
no longer be activated by RA, rather it was signiﬁcantly
repressed by RA (Figure 3A, right). As a control,
PCAF was also overexpressed in the undiﬀerentiated
cells, where TR2 was eﬀectively activated by RA
(Figure 3A, left).
The role of GRIP1 has been proposed as a coactivator
(33–35). However in the 3T3-L1 system, GRIP1 could
be associated with either the coactivator or the corepressor
complex (Figure 2C). To clarify the role of GRIP1, it was
overexpressed in the undiﬀerentiated and diﬀerentiated
cells (Figure 3B). Diﬀerential regulation of TR2 by RA in
these two cell populations was not altered by additional
GRIP1, indicating that GRIP1 was not a deciding factor
for the activity of the coregulatory complexes in regulating
the expression of TR2 in this particular culture system.
Instead, GRIP1 probably just served as a platform
molecule for facilitating the formation of ligand-induced
regulatory complexes. This result supported the notion
that the expression of a potent corepressor RIP140
rendered hormone target genes responding to hormone
in a negative fashion.
Figure 3. Diﬀerential regulation of TR2 by RA in the presence of
diﬀerent coregulators in 3T3-L1. (A) 3T3-L1 preadipocytes were
transiently transfected with PCAF (left) or RIP140 (right) with or
without RA. The endogenous TR2 mRNA expression in preadipocytes
was evaluated by RT-PCR (top panel). The expression of GRIP1,
PCAF and RIP140 and internal control actin, was monitored (bottom
four panels). (B) The endogenous TR2 mRNA expression in
undiﬀerentiated (left) and diﬀerentiated (right) cells transfected with
GRIP1 was analyzed by RT-PCR.
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domain ofGRIP1 and theamino terminal domainof RIP140
The p160 family coregulators can directly interact
with PCAF. The GRIP1–PCAF coactivator complex is
frequently detected on hormone-activated gene promoters
(35,36). Our ﬁnding that RIP140 was also co-precipitated
with receptor–GRIP1 complex (Figure 2C) would suggest
that GRIP1 could probably interact with RIP140. To test
this possibility, GST pull-down assays were conducted
(Figure 4). GRIP1 indeed directly interacted with RIP140
through its carboxyl terminal domain containing the
activating domain 2 (AD2) (Figure 4A, lower right
panel). Further tests using dissected RIP140 fragments
revealed that RIP140 directly interacted with GRIP1
through its amino terminal domain (Figure 4B, lower
panel). The observation that GRIP1 directly interacted
with RIP140, together with the reported phenomenon that
GRIP1 directly interacted with PCAF, further supported
the notion that GRIP1 probably serves as a platform
molecule by facilitating the exchange of coregulators on
the receptor complexes.
Enzymatic activities ofreceptor–GRIP1–PCAF and
receptor–GRIP1–RIP140 complexes
The receptor–GRIP1–PCAF complex was predicted to
possess HAT activity encoded by the PCAF molecule,
whereas the receptor–GRIP1–RIP140 complex was
predicted to possess HDAC activity due to the recruitment
of HDAC3/4 by RIP140 (16,37). This prediction was
tested using in vitro enzyme assays of immunoprecipitated
receptor–coregulator complexes. The results of in vitro
assays for HAT and HDAC conducted using core histone
proteins/[
3H]-acetyl histone H4 peptide as substrates are
shown in Figure 5A and B, respectively. Only the receptor
complex containing both GRIP1 and PCAF encoded
signiﬁcant HAT activity (Figure 5A, top panel). GRIP1
had neither HAT nor HDAC activity of its own.
The receptor–RIP140 complex encoded the predicted
HDAC activity. This was fully retained in the receptor–
RIP140–GRIP1 complex (Figure 5B). The biological
eﬀects of these coregulators on RA regulation of TR2
promoter were further veriﬁed using a TR2 reporter
(Figure 5C). Addition of GRIP1 or PCAF slightly
enhanced RA activation of this reporter, and coexpression
of GRIP1 and PCAF further enhanced RA activation
of the reporter. In contrast, addition of RIP140 comple-
tely eliminated RA activation, and even further reduced
the reporter activity as compared to the uninduced
control. Coexpression of GRIP1–RIP140 further
repressed the reporter activity, which could not be rescued
by PCAF. These results validated the enzymatic basis
for the coactivator complex GRIP1–PCAF and corepres-
sor complex GRIP1–RIP140.
Dynamics of RA-induced coregulator recruitment tothe
endogenous TR2promoter in cells before andafter
differentiation
To monitor the dynamics of diﬀerential RA-induced
coregulator recruitment to the endogenous TR2 promoter,
and the status of its chromatin histone modiﬁcation in
cells before and after diﬀerentiation, ChIP was conducted
as shown in Figure 6A. To examine this in a physiological
setting, only the endogenous proteins were analyzed.
In undiﬀerentiated cells, GRIP1 was found to be ﬁrst
recruited to the endogenous TR2 promoter (already
signiﬁcant at the ﬁrst time point: 6h after RA treatment),
Figure 4. GST pull-down assays to determine the interaction domains
of GRIP1 and RIP140. (A) Interaction domain of GRIP1.
Recombinant GST–RIP140 protein was incubated with
35S-labeled
GRIP1 full-length or fragments of GRIP1, including an amino terminal
(amino acid 5-479), an extended amino terminal (amino acid 5-765),
a central domain (amino acid 563-1121) and a C-terminal domain
(amino acid 1122-1462) (Upper panel). Interacting proteins were
resolved by SDS-PAGE and analyzed by autoradiography (Lower
right panel). Protein sample input (30%) and negative control
are shown in the lower left and lower central panels, respectively.
(B) Interaction domain of RIP140. GST–RIP full-length (amino acid
1-1161), RIP N-terminal (amino acid 1-496), RIP central (amino acid
333-1006) and RIP C-terminal (amino acid 977-1161) fragments
(upper panel) were tested against
35S-labeled GRIP1, and analyzed
by autoradiography (lower top panel). GST-protein inputs are shown
(lower bottom panel).
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12h). This coincided with histone H3 hyperacetylation
and RNA polymerase II recruitment. RIP140 was never
detected on the TR2 promoter in these undiﬀerentiated
cells during the entire course of RA treatment. In contrast,
in diﬀerentiated adipocytes before RA treatment, while
GRIP1 was constantly associated with this promoter,
PCAF association with the TR2 promoter was substan-
tially reduced as compared to the undiﬀerentiated condi-
tion. RIP140 was, initially, weakly recruited to the TR2
promoter without RA treatment. After RA addition, the
weakly associated PCAF then left the TR2 promoter
(6h after RA treatment), coinciding with the signiﬁcantly
enhanced recruitment of RIP140 and HDAC3 to this
promoter. This also coincided with the reduced histone
H3 acetylation and weaker association of RNA pol II with
this promoter after RA treatment.
To further examine if GRIP1 was physically associated
with diﬀerent types of coregulatory complexes binding to
the TR2 promoter, repeated ChIP was carried out for both
undiﬀerentiated and diﬀerentiated cells. The ﬁrst ChIP
was conducted using anti-GRIP1, followed by the
subsequent ChIP using anti-PCAF or anti-RIP140
(Figure 6B). PCAF was recruited increasingly to the
Figure 5. Activating (HAT) and repressive (HDAC) enzymatic activities of receptor–coregulatory complexes. Receptor complexes were precipitated
using anti-RAR from COS1 cells expressing various combinations of RAR, RXR, GRIP1, PCAF, RIP140 in the presence of RA. The RAR-
associated complex was monitored for (A) HAT activity (B) HDAC activity.
 P50.05 for diﬀerence from the RAR–RXR control. (C) TR2 reporter
gene (IRO-tk-luciferase) activity regulated by diﬀerent receptor–coregulator complexes in the presence of RA or vehicle was monitored in COS1.
The fold relative luciferase activity (RLU) was obtained by normalizing to the internal control lacZ activity.
 P50.04 for diﬀerence from the control.
Bracket indicates no signiﬁcant diﬀerence.
2276 Nucleic Acids Research, 2007, Vol. 35, No. 7Figure 6. The dynamics of complex formed on the endogenous TR2 gene promoter in 3T3 L1. (A) ChIP assay for RA-induced complexes formation
on TR2 in preadipocyte (left, before) and diﬀerentiated (right, after) 3T3-L1 cells. Speciﬁc antibodies used in immunoprecipiation are shown
on the left-hand side of panels. (B) Repeated ChIP assays ﬁrst with anti-GRIP1, followed by a speciﬁc second antibody indicated on the left.
(C) TR2 expression (upper panel) and ChIP analysis (lower panel) of TR2 promoter in diﬀerentiated, RIP-knockdown MEFs. (D) A schematic
representation of RA-induced receptor–coregulator complex formation on TR2 promoter before and after cell diﬀerentiation.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2277GRIP1 complex binding to the TR2 promoter in undiﬀer-
entiated preadipocytes during the course of RA induction.
However, RA triggered its gradual dissociation from this
promoter in diﬀerentiated cells. In contrast, RIP140
was never detected on the GRIP1 complex binding
to the TR2 promoter in undiﬀerentiated cells during
the entire course of RA induction, but it was increasingly
recruited to this promoter in diﬀerentiated cells following
RA treatment.
Based upon these ChIP and Re-ChIP data, it was
concluded that, in undiﬀerentiated cells RA ﬁrst enhanced
GRIP1 recruitment to receptors occupying the TR2
promoter, followed by the recruitment of HAT-encoding
PCAF to form a receptor–GRIP1–PCAF complex on this
promoter. This resulted in the initial phase of RA
activation of the TR2 gene in the undiﬀerentiated cells
and was required for its proliferation. On the TR2
promoter in the diﬀerentiated cells where RIP140 levels
are elevated and PCAF levels are maintained, the
receptor-associated PCAF was replaced with RIP140 in
the presence of RA, forming the repressive complex that
encodes HDAC activity. This resulted in the second
phase of RA action, i.e. the repression of TR2 probably
because TR2 was no longer needed in diﬀerentiated cells.
The dynamics of diﬀerential recruitment of various
RA-dependent coregulators to the target TR2 promoter
underlined the biphasic eﬀects of RA on the expression
of TR2 in this culture system.
Other studies on MEFs showed an elevation of RIP140
in diﬀerentiated cells (38). To determine if RIP140
plays a role in the transition from hormone-activated
to hormone-repressed phases in MEFs, and if it is
important for formation of diﬀerent complexes in the
MEF cells, RIP140-knockdown MEFs were generated,
which were monitored for adipogenesis and by ChIP
assays. TR2 expression, both before and after diﬀerentia-
tion, was similarly upregulated by RA in the RIP140-
knockdown cells, supporting a central role for RIP140 in
the biphasic regulation of this gene by RA in the wild-type
MEF system (Figure 6C, top panel). Consistently, ChIP
assays performed on diﬀerentiated RIP140-knockdown
MEFs revealed that GRIP1 was recruited to the TR2
promoter in the diﬀerentiated cells treated with RA
(Figure 6C, lower panel). Consistently, PCAF recruitment
and histone hyperacetylation, as well as RNA polymerase
II recruitment, all occurred in these RIP140-knockdown
and diﬀerentiated MEFs, mimicking the events occurred in
the proliferating preadipocytes. This validated a functional
role for RIP140 in the biphasic regulation of the RA target
gene, TR2, in this system. The model for the biphasic
regulation of the RA target gene in MEFs is illustrated
in Figure 6D. This mechanism could potentially equip
cells with the capacity to regulate the expression of certain
important genes, such as TR2, at a level that was required
for eﬃcient proliferation in preadipocytes.
TR2mediates the proliferating effect ofRA in 3T3-L1
preadipocytes
The target genes of TR2 that could mediate cell
proliferation were searched. Myelocytomatosis oncogene
(Myc), which is known to play a role in 3T3-L1
preadipocyte proliferation and diﬀerentiation (39,40),
was ﬁrst examined. c-Myc expression directly correlated
with TR2 expression in the initial screening. To validate
this ﬁnding, the expression pattern of Myc in RA-treated,
or TR2-overexpressing, preadipocytes was examined
(Figure 7A). The expression of Myc was elevated
following RA treatment (bottom panel). Interestingly,
the kinetics of Myc expression also closely paralleled the
kinetics of TR2 elevation induced by tetracycline (top
panel). A direct causal relationship of TR2 and c-Myc
expression was further conﬁrmed in TR2-knockdown cells
(Figure 7B), where c-Myc expression could no longer be
eﬀectively activated by RA. As a control, scramble
RNA was included and normal RA-stimulated c-Myc
expression was observed.
RA is known as a natural proliferating agent for
preadipocytes (21) but not for diﬀerentiated cells.
Our data (Figure 2A) revealed that thymidine incorpora-
tion was gradually increased in the preadipocyte culture
following RA treatment, coinciding with the parallel
activation of TR2 by RA in these cells. Knockdown of
TR2 in these cells reduced their basal proliferative rates
(Figure 1A). The functional role of TR2 in RA-stimulated
proliferation was then examined in TR2 knockdown and
control cells that were then treated with RA. As shown in
Figure 7C, the scramble RNA-treated cells incorporated
normal levels of labeled thymidine, which were increased
approximately 5–6-fold by RA treatment. In contrast,
TR2-knockdown cells incorporated labeled thymidine at
approximately 50% of the control level without additional
RA. The addition of RA to these TR2-knockdown cells
could no longer signiﬁcantly enhance thymidine incor-
poration. Therefore, these TR2-knockdown cells were
defective in their normal proliferation. The eﬀect was
especially severe in the case of RA-stimulated cellular
proliferation. These data strongly supported our
hypothesis that TR2 mediates the proliferative eﬀect of
RA in the undiﬀerentiated 3T3-L1 preadipocytes.
Its action involved the activation of a potential down-
stream eﬀector, c-Myc.
As a result of reduced cellular proliferation, TR2
knockdown in these cells signiﬁcantly improved their
capacity for fat accumulation, as monitored qualitatively
by oil-red-O staining (Figure 7D) and quantitatively
by measuring the accumulation of tri-glyceride/mg
protein (Figure 7E). This coincided with the physiologi-
cal eﬀects of RA in reduced adipogenesis (22,41,42).
It is likely that as these preadipocytes became
deﬁcient in proliferation, they might diﬀerentiate better.
This requires further studies to monitor marker genes
for diﬀerentiation in cells with complete knockdown
of TR2 in the future.
DISCUSSION
A functionalrole forTR2in preadipocyte proliferation
In studies using tetracycline to induce TR2 expression,
it was found that TR2 elevation could stimulate pre-
adipocyte proliferation. In contrast, TR2-knockdown
2278 Nucleic Acids Research, 2007, Vol. 35, No. 7preadipocytes proliferated less well. Studies of down-
stream eﬀectors of TR2 conﬁrmed a causal relationship of
TR2 action in the expression of c-Myc, a known cell
growth and diﬀerentiation factor of 3T3-L1 (39,40).
But the exact mode of TR2 action, in terms of the
regulation of Myc gene and other downstream eﬀectors,
remains to be determined.
The role of GRIP1 inthe formationof different
receptor–coregulator complexes
The TR2 gene responds diﬀerentially to the RA
signal, depending upon the availability of the types of
coregulators in the cells. PCAF consistently acted
as an RA-dependent coactivator and RIP140 as an
RA-dependent corepressor. The role of GRIP1 appeared
to be more complicated. GRIP1 belongs to the p160
family of proteins that includes SRC-1, TIF2/GRIP1 and
RAC3/ACTR/pCIP/AIB-1, all interacting with nuclear
receptors through LXXLL-motifs called NR boxes.
They also seemed to be involved in recruiting secondary
coactivators [reviewed in (34,43)]. Recently, GRIP1 was
suggested to act as a indirect repressor by unknown
mechanisms (44–46). Our ﬁndings provide a mechanistic
basis for a role for GRIP1 in the formation of either
ligand-dependent coactivators or ligand-dependent
corepressors. Its role might be better described as a
platform molecule that functions by directly interacting
with various coregulators and facilitating the formation
of receptor–coregulator complexes. It would be important
to determine the molecular basis underlying the diﬀer-
ential interaction of GRIP1 with various coregulators.
In terms of its biological function, it remains to be
determined whether GRIP1 is essential for all the
complexes with which it can associate. As PCAF and
RIP140 can directly associate with RAR–RXR (17,18),
it is possible that the platform function of GRIP1 might
not be required for all complexes. Rather, it could be
speciﬁc to certain promoters and in particular cell types
Figure 7. TR2 as a mediator of RA-stimulated proliferation of 3T3-L1 preadipocytes. (A) Expression of Myc a possible downstream target gene of
TR2 was monitored in TR2-inducible clones (top panel) and in RA-stimulated regular preadipocytes (bottom panel). (B) Expression of c-Myc
protein and (C) preadipocyte proliferation in TR2-silenced 3T3-L1 preadipocyte, with or without RA. (D) Parameters for fat accumulation was
monitored qualitatively by oil-red-O staining and (E) quantitatively by tri-glycerides/mg protein as a function of TR2 silencing.
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noting that TIF2 is highly expressed in preadipocytes and
has been documented to exert a physiological role in
obesity (48). In terms of the enzymatic activity, GRIP1 is
important for PCAF complex formation, but by itself
encodes no HAT activity. Further, it does not seem to
aﬀect the HDAC enzyme activity recruited by the RIP140
complex. Quite likely, the role of GRIP1 in diﬀerent
receptor–coregulator complexes might vary in diﬀerent
contexts. This is further supported by the observation that
GRIP1 interacts with RIP140, CARM1 and PRMT1
through its C-terminal domain (AD2) (49), while it
interacts with HAT proteins such as p300/CBP, GCN5
and PCAF through its AD1 (34). Dissociation of PCAF
from AD1 domain of GRIP1 in diﬀerentiated cells could
be attributed to conformational changes in AD1 domain
caused by the binding of RIP140 to AD2, steric
interference by bound RIP140, or diﬀerent aﬃnities.
Recently, we found that PRMT1 expression was elevated
during adipogenesis and that RIP140 could be methylated
by directly associating with PRMT1 (50). It would
be interesting to examine the potential role for PRMT1
in the adipogenesis model.
Differential recruitment of variousligand-dependent
regulatory complexes tothe same hormone targetgene
The dogma of diﬀerential coregulator recruitment to a
speciﬁc target gene has focused on the recruitment of
typical aporeceptor–corepressor complexes in the absence
of hormones and the recruitment of typical holoreceptor–
coactivator complexes in the presence of ligands (24,25).
This current study proposes a modiﬁed version of
diﬀerential recruitment of coregulator complexes to the
same target, especially in the presence of hormone.
This modiﬁed model could address the molecular basis
for the very diﬀerent behaviors of a gene in response
to ligands. This model also provides insight into the
complexity of hormonal regulation that requires a very
precise physiological tuning. While it is unclear whether
the behavior of the TR2 gene in response to hormonal
inputs in the 3T3-L1 system can be generalized and
applied to many other hormone-regulated genes, it is
likely that most hormone target genes require an eﬃcient
mechanism to ﬁne-tune their expression in order
to eﬀectively respond to the speciﬁc need of the cells
(51–53). The presence of certain potent tissue- or cell-
speciﬁc negative coregulators such as RIP140 is likely
to be one important factor in ﬁne-tuning the expression
of important cellular components.
Our initial model of diﬀerential ligand-dependent
coregulator recruitment was based largely upon in vitro
kinetic studies and transfection experiments using recon-
stituted expression of coregulators (13,15,54). This current
study presents the ﬁrst example where this model could
apply in a natural, physiologically relevant condition.
However, due to the technical limitation of ChIP and
Re-ChIP experiments, it was diﬃcult to evaluate many
other components coexisting in the molecular complexes
in real time and in vivo. Future challenges remain with
regard to the identiﬁcation of the exact components of
physiologically relevant receptor–coregulator complexes
for a speciﬁc target gene and under speciﬁc physiological
conditions. The kinetic factors deduced from in vitro
protein interaction tests could provide clues for building
models to be tested (17,26). Ultimately, it requires
examination of the model on a real gene by taking into
account the various cellular environments, where the
availability of individual component may ﬂuctuate widely.
A functionalrole forTR2in mediating thephysiological
action of RAin preadipocytes
Adipocytes are a specialized cell type that store energy
in the form of lipids. Obesity results from the over-
development of white fat and high adiposity is associated
with systemic disturbances in cellular diﬀerentiation
or proliferation such as deregulation of adipocyte
diﬀerentiation or preadipocyte proliferation (55,56).
RA is known to enhance preadipocyte proliferation (21)
and inhibit adipocyte diﬀerentiation (19,20,57–60).
Our study presents the ﬁrst evidence for the function of
TR2 in mediating RA-stimulated preadipocyte prolifera-
tion. The possibility of other RA mediators (or eﬀectors)
in preadipocyte proliferation has not been excluded.
As a mediator for the RA signal to stimulate
preadipocyte proliferation, TR2 would need to be
activated by RA in the preadipocytes. This is consistent
with its rapid induction by RA in these cells and conﬁrmed
in studies using tetracycline to induce TR2 expression
without RA addition. Consistently, TR2-knockdown
preadipocytes were less proliferative and can no longer
eﬀectively respond to the mitogenic eﬀect of RA. We also
identiﬁed c-Myc as a probable downstream eﬀector of
TR2. Thus, one of the signaling pathway of RA in
preadipocyte proliferation can be mediated by RARs
and RXRs (22,41,42) that regulate TR2, which in turns
regulates Myc.
The second phase of RA eﬀect on the expression of
TR2 in the diﬀerentiated cells suggests that TR2 expres-
sion is no longer needed in the diﬀerentiated cells because
the diﬀerentiated cells cease proliferation. Alternatively,
it is possible that TR2 needs to be reduced in these
diﬀerentiated cells when they are exposed to RA. This may
be due to a potential anti-diﬀerentiation eﬀect of TR2 that
remains to be evaluated. Based upon the expression
studies, TR2 levels are generally high in early develop-
mental stages and in proliferating cells, but are usually not
detected in diﬀerentiated cells. Previous studies of ectopic,
forced TR2 expression showed that it mostly resulted
in apoptosis (4). This would suggest a potential detri-
mental eﬀect of TR2 in certain cells when they undergo
diﬀerentiation or are fully diﬀerentiated. This also
requires further studies.
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